Introduction of mRNA-Based Flu Vaccine
The US Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, manufacturer Moderna said. The shot, named mFlusiva, is intended for adults age 50 or older.
Implications for Indian Businesses
Although the approval of mFlusiva is a US-based development, it may have implications for India's healthcare sector. Indian businesses in the healthcare sector may need to consider the impact of such advancements on their operations and strategies. The use of mRNA technology in vaccine development may also open up new opportunities for Indian companies involved in healthcare and pharmaceuticals.
Key Features of mFlusiva
Some key features of mFlusiva include:
- Intended for adults age 50 or older
- Made with mRNA technology
- Approved by the US FDA
- May provide protection against flu viruses
- Could have implications for India's healthcare sector